Invitae
May Lag for Many Dx Firms' Stock Prices as 360Dx Index Drops 4 Percent
Of the 30 companies in the index, 18 firms saw their stock prices decrease, while 12 firms' share prices increased.Â
Invitae Sues Natera Alleging Infringement of Patent on DNA Sequencing Assembly Technique
Invitae believes its '799 patent improves upon prior art and wants a US District Court to find that Natera is infringing its IP with its Signatera test.
Invitae Q1 Revenues Increase 61 Percent
The company reported revenues of $103.6 million, exceeding the consensus Wall Street estimate.
In Brief This Week: Unilabs, PerkinElmer, Invitae, Becton Dickinson, and More
News items for the in vitro diagnostics industry for the week of April 19, 2021.
Invitae Acquiring Genosity for $200M; Investment Group Provides Firm $1.15B in Senior Notes
Invitae expects that Genosity's software and data management platform will allow it to quickly advance several oncology tests in development.
Feb 17, 2021
Invitae Q4 2020 Revenues Increase 51 Percent
Feb 1, 2021
Oppenheimer Downgrades Invitae to Perform Rating
Jan 22, 2021
Invitae Prices $400M Common Stock Offering
Jan 20, 2021
Invitae to Raise $400M in Proposed Public Offering
Jan 11, 2021
Invitae 2020 Preliminary Revenues Rise 28 Percent
Nov 5, 2020